These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34247834)

  • 41. The routes to orphan drug designation--our recent experience at the FDA.
    Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
    Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
    [No Abstract]   [Full Text] [Related]  

  • 42. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF.
    Zile MR; Abraham WT; Lindenfeld J; Weaver FA; Zannad F; Graves T; Rogers T; Galle EG
    Am Heart J; 2018 Oct; 204():139-150. PubMed ID: 30118942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 45. Reproducibility probability in clinical trials.
    Shao J; Chow SC
    Stat Med; 2002 Jun; 21(12):1727-42. PubMed ID: 12111908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Not Available].
    Banzi R
    Recenti Prog Med; 2019 Nov; 110(11):526-527. PubMed ID: 31808433
    [No Abstract]   [Full Text] [Related]  

  • 47. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
    Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
    Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA; Freeman SN; Imoisili MA; Coté TR
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improving access to medicines: empowering patients in the quest to improve treatment for rare lethal diseases.
    Halpin L; Savulescu J; Talbot K; Turner M; Talman P
    J Med Ethics; 2015 Dec; 41(12):987-9. PubMed ID: 23839261
    [No Abstract]   [Full Text] [Related]  

  • 51. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 52. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accelerating orphan drug development.
    Coté TR; Xu K; Pariser AR
    Nat Rev Drug Discov; 2010 Dec; 9(12):901-2. PubMed ID: 21119719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience With the Priority Review Voucher Program for Drug Development.
    Kesselheim AS; Maggs LR; Sarpatwari A
    JAMA; 2015 Oct; 314(16):1687-8. PubMed ID: 26414802
    [No Abstract]   [Full Text] [Related]  

  • 57. Orphanage at the FDA.
    Chen E
    J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
    [No Abstract]   [Full Text] [Related]  

  • 58. Accelerated approval of oncology drugs: can we do better?
    Ellenberg SS
    J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
    [No Abstract]   [Full Text] [Related]  

  • 59. External control arms for rare diseases: building a body of supporting evidence.
    Khachatryan A; Read SH; Madison T
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):501-506. PubMed ID: 37095406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Which efficacy trials for drugs for rare diseases?].
    Traversa G; Trotta F
    Epidemiol Prev; 2017; 41(5-6):318-319. PubMed ID: 29119773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.